What's Happening?
Kelun-Biotech has presented promising results from multiple clinical studies on its TROP2 ADC sacituzumab tirumotecan (sac-TMT) at the 2025 Chinese Congress on Holistic Integrative Oncology. The studies focused
on the efficacy and safety of sac-TMT in treating various cancers, including endometrial cancer and non-small cell lung cancer (NSCLC). In a Phase II study for endometrial cancer, sac-TMT showed a confirmed objective response rate of 30.7% in the 4 mg/kg group and 34.1% in the 5 mg/kg group. For NSCLC, sac-TMT demonstrated a disease control rate of 85.7% with a median progression-free survival of 9.5 months. These findings suggest sac-TMT's potential as a viable treatment option for these cancers.
Why It's Important?
The results presented by Kelun-Biotech highlight significant advancements in cancer treatment, particularly for patients with advanced or metastatic cancers who have limited options. Sac-TMT's promising efficacy and manageable safety profile could offer new hope for patients with endometrial cancer and NSCLC, potentially improving survival rates and quality of life. The ongoing global Phase 3 studies of sac-TMT could further validate its effectiveness and lead to broader availability, impacting the pharmaceutical industry and healthcare providers by introducing a new treatment option.
What's Next?
Kelun-Biotech is continuing its research with ongoing Phase 3 studies of sac-TMT in combination with pembrolizumab for NSCLC. These studies aim to further assess the drug's efficacy and safety, potentially leading to regulatory approval and commercialization. The company's commitment to developing innovative drugs through its proprietary ADC and novel DC platform could result in more breakthroughs in cancer treatment, addressing unmet medical needs and enhancing patient outcomes.
